Table 2. Embolotherapies for multifocal breast cancer liver metastasis.
| Reference | Year | n | Treatment modality | OS | Other survival outcomes | Response criteria | Response rate | AE rate |
|---|---|---|---|---|---|---|---|---|
| Maes et al 59 | 2008 | 30 | Drug-eluting bead TACE | 7 mo | PFS: 3 mo | PERCIST | 3-mo DC: 44% | 20% grade 3 and higher AE |
| Vogl et al 43 | 2010 | 208 | Conventional TACE | 25 mo | RECIST | 3-mo DC: 64% | 0% major AE | |
| Cho et al 60 | 2010 | 10 | Drug-eluting bead TACE | 26 mo | RECIST | 1-mo DC: 50% | 70% any AE | |
| Duan et al 61 | 2011 | 44 | Drug-eluting bead TACE | 1-y OS: 63% 2-y OS: 48% 3-y OS: 28% |
RECIST | 1–3-mo DC: 84% | 77% any AE | |
| Martin et al 42 | 2012 | 40 | Drug-eluting bead TACE | PFS: 17 mo | RECIST | 1-mo DC: 90% | 17% any AE | |
| Nielsen et al 62 | 2012 | 16 | Drug-eluting bead TACE | 25 mo | PFS: 8 mo | RECIST 1.1 | 1-mo DC: 50% | 13% grade 3 and higher AE |
| Eichler et al 63 | 2013 | 43 | Drug-eluting bead TACE | 12 mo | RECIST | 3-mo DC: 44% | 20% any AE | |
| Damian et al 64 | 2013 | 14 | Drug-eluting bead TACE | 26 mo | RECIST | |||
| Lin et al 65 | 2017 | 23 | Drug-eluting bead TACE | 17 mo | RECIST 1.1 | 3-mo DC: 83% | 35% major AE | |
| Li et al 45 | 2005 | 28 | Drug-eluting bead TACE | 28 mo | WHO | 3-mo DC: 71% | 0% grade 3 and higher AE | |
| Chang et al 44 | 2018 | 17 | Drug-eluting bead TACE | 5 mo | mRECIST | 3-mo DC: 29% | 9% grade 3 and higher, 71% any AE | |
| Haug et al 39 | 2012 | 58 | Resin TARE | 11 mo | RECIST 1.1 | 3-mo DC: 66% | ||
| Cianni et al 35 | 2013 | 77 | Resin TARE | 11 mo | RECIST | 2-mo DC: 80% | 3% grade 3, 7% grade 1–2 AE | |
| Saxena et al 32 | 2014 | 40 | Resin TARE | 11 mo | RECIST | 3-mo DC: 70% | 40% grade 1–2 AE | |
| Gordon et al 66 | 2014 | 75 | Resin TARE | 7 mo | RECIST | 1-mo DC: 98% | 8% grade 3 and higher AE | |
| Pieper et al 36 | 2016 | 44 | Resin TARE | 6 mo | RECIST 1.1 | 3-mo DC: 82% | 2% grade 3 and higher AE | |
| Bangash et al 67 | 2007 | 27 | Glass TARE | 6 mo | WHO | 3-month DC 91% | 11% grade 3 and higher AE | |
| Fendler et al 34 | 2016 | 81 | Glass and resin TARE | 8 mo | PERCIST | 3-mo OR: 52% | <10% grade 3 and higher AE | |
| Deipolyi et al 38 | 2018 | 31 | Glass and resin TARE | 11 mo | PERCIST | 3–5-mo OR: 69% | 12% major AE | |
| Chang et al 44 | 2018 | 30 | Glass and resin TARE | 13 mo | mRECIST | 3-mo DC: 47% | 0% grade 3 and higher, 44% any AE | |
| Deipolyi et al 41 | 2019 | 49 | Glass and resin TARE | 11 mo | PERCIST | 3–5-mo OR: 75% | 8% grade 3 and higher AE |
Abbreviations: AE, adverse event; DC, disease control including stable disease, partial response, and complete response; mRECIST, modified RECIST; OR, objective response, including partial and complete response; OS, overall survival; PERCIST, Positron Emission Tomography Response Criteria In Solid Tumors; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; TACE, transarterial chemoembolization; TARE, transarterial radioembolization; WHO, World Health Organization.
Notes: Selected studies are presented. Survival reported as median value from the time of treatment; n indicates number of breast cancer patients studied.